Cardiology Medical News about Atherosclerosis Phospholipases A2

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic
Expert Opinion on Investigational Drugs, 09/18/09

Suckling KE – Phase II results of the trials of two phospholipase A2 inhibitors which may be of value in the treatment of atherosclerosis and cardiovascular disease have been reported in the past year. Darapladib (GlaxoSmithKline) is an inhibitor of lipoprotein–associated phospholipase A2 and varespladib (Anthera) inhibits several forms of the secreted phospholipase A2s. Despite the apparent similarity of mechanism, which is also built into the compounds' names, the role of the two types of phospholipase in atherogenesis is very different. Evidence for this comes from a range of preclinical studies and from epidemiological data which are summarised here. These data provide a basis for the Phase II studies and support decisions to move into Phase III, a decision which in the case of darapladib has been made and studies commenced (STABILITY trial). For varespladib the FRANCIS–ACS trial in acute coronary syndrome patients is in progress.

<< Previous
Five-year clinical outcomes after coronary stenting of chronic...

Next >>
Sexual activity and erectile dysfunction in elderly men with...

Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia
Journal of Clinical Lipidology, 10/14/09 Relevance Score: 78%

Heritability of Thromboxane A2 and Prostaglandin E2 Biosynthetic Machinery in a Spanish Population
Arteriosclerosis, Thrombosis, and Vascular Biology, 10/26/09 Relevance Score: 64%

Increased levels of circulating microparticles in primary Sjogrens syndrome, systemic lupus erythematosus and rheumatoid arthritis, and relation with disease activity
Arthritis Research & Therapy, 10/20/09 Relevance Score: 64%

Impact of group IVA cytosolic phospholipase A2 gene polymorphisms on phenotypic features of patients with familial adenomatous polyposis
International Journal of Colorectal Disease, 10/08/09 Relevance Score: 64%

Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug
Atherosclerosis, 10/07/09 Relevance Score: 64%